{
  "id": 8334296,
  "title": "Revolution Medicines chief development officer sells $67,940 in stock",
  "url": "https://urgent.news/2026/09/18/revolution-medicines-chief-development-officer-sells-67-940-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T23:30:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/revolution-medicines-chief-development-officer-sells-67940-in-stock-93CH-4907990"
  },
  "original_language": "en",
  "account": "Alan B. Sandler, the Chief Development Officer at Revolution Medicines, sold 341 shares of the company's common stock worth $67,940 on September 16, 2026. The sale price per share ranged from $194.9589 to $199.3032. This transaction, as per the company's Rule 10b5-1 instruction letter adopted on June 13, 2026, was intended to meet tax withholding obligations following the vesting of restricted stock units. Sandler's stock holdings are now valued at 52,868 shares, comprising 209 shares from the Employee Stock Purchase Plan and 52,350 restricted stock units. Despite RVMD shares experiencing a 322% increase over the past year, the sale occurred at elevated prices near $200 per share. Presently, InvestingPro analysis suggests the stock is overvalued. Recently, Revolution Medicines announced the FDA approval of its drug Rasonque (daraxonrasib) for treating second-line metastatic pancreatic ductal adenocarcinoma, based on the RASolute 302 study. This approval has led to adjusted outlooks from various financial firms, with Morgan Stanley initiating coverage with an overweight rating, Needham raising its price target to $275, Guggenheim increasing to $265, and H.C. Wainwright raising to $280.",
  "summary": null,
  "key_points": [
    "Alan B. Sandler sold 341 shares of Revolution Medicines stock on September 16, 2026.",
    "Sale price ranged from $194.96 to $199.30 per share, totaling $67,940.",
    "Sandler's holdings now valued at 52,868 shares, despite RVMD's 322% stock increase."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Revolution Medicines officer sells $353,449 in shares",
        "url": "https://urgent.news/2026/09/18/revolution-medicines-officer-sells-353-449-in-shares",
        "published": "2026-09-18T23:30:55.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}